Researchers are excited about this new drug, a innovative dual agonist showing significant outcomes in initial trials for size management. It functions by modulating several pathways : GLP-1 and GIP, which , when activated , assist influence appetite and enhance energy expenditure . Preliminary findings demonstrate substantial body management and l